Association of p53 tumor suppressor gene with paraclinical and clinical modalities of gliomas patients in Malaysia

Acta Neurochirurgica

Volumn 146, Issue 6, 2004, Pages 595-601

  Yusoff, A A ^a   Abdullahl, Jafri ^a,b   Abdullah, M R ^a   Mohd Ariff, A R ^a   Isa, M N ^a  

^a SCHOOL OF PHYSICS   (Malaysia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

Gliomas; Malaysian; P53 tumor suppressor gene; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC VARIABILITY; GLIOMA; HUMAN; MALAYSIA; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; ASTROCYTOMA; BASE PAIRING; BRAIN NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; FRAMESHIFT MUTATION; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALAYSIA; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2942703938     PISSN: 00016268     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00701-004-0250-3     Document Type: Article

References (42)

1. Abdullah J, Isa MN (1999) Analysis of brain tumours suitable for curability via gene therapy in North East Malaysia. Stereotact Funct Neurosurg 73: 19-22
2. Abdullah J, Ridzuan MY (1997) Incidence of tumors suitable for radiosurgery in a developing country like Malaysia: retrospective study done before the decision to start a radiosurgery programme. Stereotact Funct Neurosurg 69: 152-155
3. Allred DC, Clark GM, Elledge R (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206
4. Annual report (1998) Ministry of Health Malaysia
5. Black PM (1991) Brain tumors part 1. N Eng J Med 324(21): 1471-1476
6. Chozick BS, Pezzullo JC, Epstein MH, Finch PW (1994) Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-837
7. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R, Jenkins R, Yandell D, Seizinger BR (1991) TP53 gene mutations and 17p deletions in human astrocytomas genes. Chrom Cancer 3: 323-331
8. Danks RA, Chopra G, Gonzales MF, Orian JM, Kaye AH (1995) Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytomas. Neurosurgery 37: 246-254
9. Fisher CM (1967) Some Neuro-opthalmological observations. J Neurol Neurosurg Psychiatry 30: 383-392
10. Frankel RH, Bayona W, Koslow M, Newcomb EW (1992) p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427-1433
11. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM (1992) p53 mutations and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 52: 674-679
12. Goh H, Yoa J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
14. Hartmann A, Blaszyk H, Kovach J, Sommer S (1997) The molecular epidemiology of p53 gene mutations in breast cancer. Trends Genet 13: 27-33
15. Hilderbrand J, Dewitte O, Dietrich PY, de Tribolet N (1997) Management of brain tumors. Eur Neurol 38(3): 238-253
16. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR (1998) Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42: 724-729
17. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 66: 373-385
18. Karnofsky DA, Burchenal JH (1949) In evaluation of chemotherapy agents. In: Macleod CM (ed) Columbia University Press, New York pp 191-205
19. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Cancer 76: 72-78
20. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumours of the central nervous system. Springer, Berlin Heidelberg New York Tokyo
21. Kraus JA, Glessmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U (2000) Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme, J Neurooncol 48(2): 89-94
22. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM (1994) Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res 1:1617-1622
23. Lane DP (1992) P53, guardian of the genome. Nature 358: 15-16
24. Lote K, Egeland T, Hoger B, Skulleriad K, Hirschberg H (1998) Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J Neuroloncol 40(2): 161-170
25. Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
26. Okumura A, Takenaka K, Nishimura Y, Asano Y, Sakai N, Kuwata K, Era S (1999) The characterization of human brain tumor using magnetization transfer technique in magnetic resonance imaging. Neuro Res 21(3): 250-254
27. Orita M, Iwahana H, Hayashi K, Sekiya T (1989) Detection of polymorphisms using the polymerase chain reaction. Genomic 5: 874-879
28. Pardo F, Hsu D, Hedley-Whyte E, Efird J, Schmidt E (1993) High p53 expression is prognostic of overall survival in adult supratentorial astrocytoma patients. J Neurooncol. 15: S19
29. Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations p53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8(5): 1117-1124
30. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V. Burkert W (1997) Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 35: 13-28
31. Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H (2001) The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 55(3): 195-204
32. Ropper AH (1986) Lateral displacement of the brain and level of consciousness in patients with acute hemispheral mass. N Eng J Med 314: 953-958
33. Sarkar FH, Kupsky WJ, Li Y-W, Sreepathi P (1994) Analysis of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand conformation polymorphism and DNA sequencing. Diag Mol Path 3(1): 2-8
34. Shinoda J, Sakai N, Nakatanik, Funakoski T (1998) Prognostic factors in supratentorial WHO grade II astrocytoma in adults. Br J Neurosurg 12(4): 318-324
35. Simmons ML, Lamborn KR, Takahasbi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG, Aldape K (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61(3): 1122-1128
36. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K (1994) p53 immunohistochemical positivity as prognostic marker in intracranial tumors. APMIS 102: 786-792
37. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y. Shinohe Y (1998) Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 58: 1793-1797
38. Thor AD, Moore DH II, Edgerton SM (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84: 845-855
39. Tynninen O, Aronen HJ, Ruhala M, Paetau A, Von Boguslawski K, Salonen O, Jaaskelainen J, Paavonent (1999) MRI enhancement and microvascular density in gliomas correlation with tumor cell proliferation. Invest Radiol 34(6): 427-434
40. Van Meyel DJ, Ramsay DA, Casson AG, Keeny M, Chambers AE, Caimcross JG (1994) p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J Natl Cancer Inst 86: 1011-1017
41. Wessbecher FW, Maravilla KR, Dalley RW (1991) Optimizing brain MR imaging protocols with gadopentetate dimenglumine: enhancement of intracranial lesions on spin-density and T2-weighted images. AJNR 12(4): 675-679
42. Yasoff MR, Abdullah J, Isa MN (1998) Brain tumours in rural North East Malaysia. J Islamic Acad Sci 11(4): 121-129